keyword
MENU ▼
Read by QxMD icon Read
search

Omalizumab

keyword
https://www.readbyqxmd.com/read/28089687/stabilizing-effects-for-antibody-formulations-and-safety-profiles-of-cyclodextrin-polypseudorotaxane-hydrogels
#1
Taishi Higashi, Naoko Ohshita, Tatsunori Hirotsu, Yoshihito Yamashita, Keiichi Motoyama, Sawako Koyama, Ruriko Iibuchi, Takayuki Uchida, Shiuhei Mieda, Kenji Handa, Tomoaki Kimoto, Hidetoshi Arima
Antibodies often have poor physicochemical stability during storage and/or transport, which is a serious drawback for the development of antibody-based drugs. In this study, we prepared polypseudorotaxane (PPRX) hydrogels consisting of cyclodextrins (CyDs) and polyethylene glycol (PEG), and evaluated them as stabilizers for commercially available antibody-based drugs. α-CyD and γ-CyD formed PPRX hydrogels with PEG (MW 20,000 Da) in the presence of antibody-based drugs such as omalizumab, palivizumab, panitumumab, and ranibizumab...
January 12, 2017: Journal of Pharmaceutical Sciences
https://www.readbyqxmd.com/read/28078079/looking-forward-to-new-targeted-treatments-for-chronic-spontaneous-urticaria
#2
REVIEW
Emek Kocatürk, Marcus Maurer, Martin Metz, Clive Grattan
The introduction of omalizumab to the management of chronic spontaneous urticaria (CSU) has markedly improved the therapeutic possibilities for both, patients and physicians dealing with this disabling disease. But there is still a hard core of patients who do not tolerate or benefit from existing therapies and who require effective treatment. Novel approaches include the use of currently available drugs off-licence, investigational drugs currently undergoing clinical trials and exploring the potential for therapies directed at pathophysiological targets in CSU...
2017: Clinical and Translational Allergy
https://www.readbyqxmd.com/read/28051241/effects-of-omalizumab-therapy-on-allergic-rhinitis-a-pilot-study
#3
S Masieri, C Cavaliere, E Begvarfaj, D Rosati, A Minni
OBJECTIVE: The use of omalizumab, a humanized monoclonal antibody able to binding Ig-E, is currently authorized only for treatment of severe bronchial asthma. The use of omalizumab in other Ig-E related diseases is off-label, although some studies have provided promising results about it. The aim of this study was to evaluate if therapy with omalizumab in patients affected by asthma and allergic rhinitis has an impact also on allergic rhinitis-related symptoms. PATIENTS AND METHODS: A longitudinal study was conducted on 11 patients affected by severe asthma and a periodic allergic rhinitis...
December 2016: European Review for Medical and Pharmacological Sciences
https://www.readbyqxmd.com/read/28042528/desensitization-for-peanut-allergies-in-children
#4
Rekha D Jhamnani, Pamela Frischmeyer-Guerrerio
Immunotherapy for peanut allergy has been an exploding topic of study within the last few years. Sublingual, epicutaneous, and oral immunotherapy are being investigated and show promise in the treatment of peanut allergy. Oral immunotherapy has shown the most clinical benefit; however, sublingual and epicutaneous immunotherapy appear to have the most favorable safety profiles. Most studies to date suggest that only a minority of subjects achieve sustained unresponsiveness to peanut after discontinuation of immunotherapy...
September 2016: Current Treatment Options in Allergy
https://www.readbyqxmd.com/read/28029407/management-of-chronic-spontaneous-urticaria-in-routine-clinical-practice-a-delphi-method-questionnaire-among-specialists-to-test-agreement-with-current-european-guidelines-statements
#5
A Giménez-Arnau, M Ferrer, J Bartra, I Jáuregui, M Labrador-Horrillo, J Ortiz de Frutos, J F Silvestre, J Sastre, M Velasco, A Valero
BACKGROUND: Chronic spontaneous urticaria (CSU) is a frequent clinical entity that often presents a diagnostic and therapeutic challenge. OBJECTIVE: To explore the degree of agreement that exists among the experts caring for patients with CSU diagnosis, evaluation, and management. METHODS: An online survey was conducted to explore the opinions of experts in CSU, address controversial issues, and provide recommendations regarding its definition, natural history, diagnosis, and treatment...
October 28, 2016: Allergologia et Immunopathologia
https://www.readbyqxmd.com/read/28017628/eosinophilic-esophagitis-during-peanut-oral-immunotherapy-with-omalizumab
#6
Caitlin M Burk, Evan S Dellon, Pamela H Steele, Yamini V Virkud, Mike Kulis, A Wesley Burks, Brian P Vickery
No abstract text is available yet for this article.
December 22, 2016: Journal of Allergy and Clinical Immunology in Practice
https://www.readbyqxmd.com/read/27995273/-partial-response-of-solar-urticaria-to-omalizumab-therapy
#7
L Kowalzick, W Thiel, C Bielfeld, H Ziegler, L Eickenscheidt
The treatment of solar urticaria is regarded as difficult. In some cases good responses to the anti-IgE antibody omalizumab (Xolair®), approved for treatment of chronic spontaneous urticaria, have been reported. We report on a 50-year-old Caucasian woman who for the last 5 years has developed localized itching and stinging erythemas following exposure to sunlight accompanied sometimes by anaphylactic reactions. Oral antihistamines in three- to four-fold doses and a topical sun screen had been only partially effective in long-term use...
December 19, 2016: Der Hautarzt; Zeitschrift Für Dermatologie, Venerologie, und Verwandte Gebiete
https://www.readbyqxmd.com/read/27993289/beneficial-effects-of-omalizumab-therapy-in-allergic-bronchopulmonary-aspergillosis-a-synthesis-review-of-published-literature
#8
REVIEW
Jian-Xiong Li, Li-Chao Fan, Man-Hui Li, Wei-Jun Cao, Jin-Fu Xu
Omalizumab, a humanized mAb that binds to IgE, has been an effective therapy for patients with severe allergic asthma; however, there are few clinical trials examining the efficacy of Omalizumab in patients with allergic bronchopulmonary aspergillosis (ABPA) except some case reports. To assess the clinical and immunological effects of Omalizumab in ABPA patients, we made a synthesis review of 102 cases from 30 published literature, analyzed the effects of Omalizumab therapy in ABPA and conducted subgroup analyses to determine factors that influenced the therapy endpoints...
January 2017: Respiratory Medicine
https://www.readbyqxmd.com/read/27976938/omalizumab-is-associated-with-reduced-acute-severity-of-rhinovirus-triggered-asthma-exacerbation
#9
David B Kantor, Molly C McDonald, Nicole Stenquist, Blake J Schultz, Craig D Smallwood, Kyle A Nelson, Wanda Phipatanakul, Joel N Hirschhorn
No abstract text is available yet for this article.
December 15, 2016: American Journal of Respiratory and Critical Care Medicine
https://www.readbyqxmd.com/read/27971622/cost-effectiveness-of-omalizumab-for-the-treatment-of-chronic-spontaneous-urticaria-in-france
#10
C Cariou, E Duteil, K Benjamin, J Duco
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27971574/the-impact-on-long-term-targeted-therapy-with-omalizumab-on-the-quality-of-life-according-to-registry-of-children-with-uncontrolled-severe-persistent-asthma-russian-experience
#11
L Namazova-Baranova, E Vishneva, E Dobrynina, A Alekseeva, J Levina, K Efendieva, Smirnov, E Antonova, N Voznesenskaya, L Selimzianova
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27971552/estimating-the-impact-associated-to-the-use-omalizumab-in-the-treatment-of-severe-persistent-allergic-asthma-in-portugal-evaluating-outcomes-and-treatment-costs-using-real-world-data-from-portuguese-patients
#12
I Moital, J Carrasco, I Cardoso, D Mesquita, J Felix, B Vandewalle
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27971550/pharmacoeconomic-analysis-of-treatment-of-adult-patients-with-severe-uncontrolled-asthma-with-omalizumab-in-russia
#13
A Kolbin, M Frolov, T Galankin
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27971549/pharmacoeconomic-analysis-of-treatment-of-children-with-severe-uncontrolled-asthma-with-omalizumab-in-russia
#14
A Kolbin, L Namazova-Baranova, E Vishneva, M Frolov, T Galankin, A Alekseeva, E Dobrynina
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27971516/feasibility-of-matching-adjusted-indirect-comparison-maic-of-omalizumab-oma-vs-mepolizumab-mepo-in-moderate-to-severe-asthma
#15
R Ayyagari, L Álvares, F Mu, V Hacking, R Martinez, J E Signorovitch
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27970590/adaptive-prediction-of-symptoms-return-upon-discontinuation-of-omalizumab-treatment-in-chronic-spontaneous-urticaria-patients
#16
D Saldana Miranda, M Ferrer, N Janssens, A Gimenez-Arnau, M Balp, S Khalil, V Risson
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27970533/pediatric-registry-of-patients-with-severe-persistent-uncontrolled-asthma-receiving-omalizumab
#17
L Namazova-Baranova, E Vishneva, E Dobrynina, A Alekseeva, J Levina, K Efendieva, V Smirnov, E Antonova, N Voznesenskaya, L Selimzianova
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27957325/immunogenicity-of-a-peptide-based-anti-ige-conjugate-vaccine-in-non-human-primates
#18
Risini D Weeratna, Ghania Chikh, Lu Zhang, James D Fraser, Jennifer M Thorn, James R Merson, Michael J McCluskie, Brian R Champion, Heather L Davis
The anti-human immunoglobulin E (IgE) monoclonal antibody, omalizumab (Xolair®, Genentech, South San Fransisco, CA), is effective in the treatment of poorly controlled moderate to severe allergic asthma and chronic idiopathic urticaria. It acts by specifically binding to the constant domain (Cϵ3) of free human IgE in the blood and interstitial fluid. Although efficacious, use of omalizumab is limited due to restrictions on patient weight and pre-existing IgE levels, and frequent dosing (q2-4 weeks). A vaccine inducing anti-IgE antibodies has the potential for similar clinical benefits with less frequent dosing and relatively lower cost of goods...
June 2016: Immunity, Inflammation and Disease
https://www.readbyqxmd.com/read/27942351/therapeutic-interventions-in-severe-asthma
#19
REVIEW
Giorgio Walter Canonica, Gianenrico Senna, Patrick D Mitchell, Paul M O'Byrne, Giovanni Passalacqua, Gilda Varricchi
The present paper addresses severe asthma which is limited to 5-10% of the overall population of asthmatics. However, it accounts for 50% or more of socials costs of the disease, as it is responsible for hospitalizations and Emergency Department accesses as well as expensive treatments. The recent identification of different endotypes of asthma, based on the inflammatory pattern, has led to the development of tailored treatments that target different inflammatory mediators. These are major achievements in the perspective of Precision Medicine: a leading approach to the modern treatment strategy...
2016: World Allergy Organization Journal
https://www.readbyqxmd.com/read/27942350/omalizumab-for-chronic-urticaria-in-latin-america
#20
Paul Wilches, Paola Wilches, Juan Carlos Calderon, Annia Cherrez, Ivan Cherrez Ojeda
BACKGROUND: Chronic urticaria (CU) is defined as the spontaneous appearance of wheals, with or without angioedema, persisting for ≥6 weeks. Chronic Spontaneous Urticaria (CSU) is a type of CU which affects 0.5-1 % of the global population, but it represents a high burden to patients. In recent years, omalizumab is available as treatment of disease. Our aim is to extend previous findings, analyzing effects of omalizumab on symptoms in Latin American patients with CSU. METHODS: Retrospective analysis of patients treated with omalizumab in Cuenca-Ecuador...
2016: World Allergy Organization Journal
keyword
keyword
7812
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"